| Wk 24 Results, n/n (%) | TCZ Monotherapy | TCZ + DMARDs | p |
|---|---|---|---|
| (N=173) | (N=532) | ||
| EULAR good + moderate response | 135/173 (78.0) | 427/532 (80.3) | 0.35 |
| ACR50 response | 72/173 (41.6) | 205/532 (38.5) | 0.78 |
| ACR70 response | 39/173 (22.5) | 94/532 (17.7) | 0.21 |
| HAQ-DI reduction from baseline ≥0.22 | 98/146 (67.1) | 315/439 (71.8) | 0.072 |
| DAS28 <2.6 | 62/142 (43.7) | 230/446 (51.6) | 0.34 |
| CDAI remission | 27/146 (18.5) | 62/436 (14.2) | 0.14 |
| SDAI remission | 29/142 (20.4) | 69/430 (16.0) | 0.15 |
p values are for the test of the “TCZ monotherapy = TCZ + DMARDs hypothesis” using logistic or linear regression models adjusted for previous treatment (DMARD-IR/TNF-IR) and baseline DAS28, CDAI or SDAI. n/n = pts who responded/evaluable pts at wk 24.